Poster
Other/Multi
ASCO 2025 | May 30-June 3,2025
Other/Multi
A phase 1, first-in-human study of DS-2243, an HLA-A*02/NY-ESO–directed bispecific T‑cell engager, in patients with advanced solid tumors
Sandra P. D'Angelo
Poster
T-DXd
AACR 2025 | April 25-29, 2025
Other/Multi
Baseline serum protein analysis of patients with interstitial lung disease/pneumonitis (ILD) in 3 trastuzumab deruxtecan (T-DXd) trials: DESTINY-Breast01, DESTINY-Breast04, and DESTINY-Lung01
Zenta Tsuchihashi
Oral
Pipeline Compounds
ESMO 2025 | October 17-21, 2025
Other/Multi
DS-3939, a tumor-associated mucin 1 (TA-MUC1)–directed antibody–drug conjugate, in patients with advanced/metastatic solid tumors: Initial results from a first-in-human study
Manish R. Patel
Poster
Valemetostat
ASCPT 2025 | May 28-31, 2025
Other/Multi
Effect of valemetostat on the pharmacokinetics of midazolam and digoxin (CYP3A and P-gp substrates): A phase 1 drug–drug interaction study in patients with refractory or relapsed non-hodgkin lymphoma
Masaya Tachibana
Poster
I-DXd
ASCO 2025 | May 30-June 3,2025
Other/Multi
KEYMAKER-U06 Substudy O6E: A phase 1/2 open-label, umbrella platform study of ifinatamab deruxtecan in combination with pembrolizumab with or without chemotherapy for first-line treatment of advanced esophageal squamous cell carcinoma
Ken Kato
Poster
T-DXd
AMCP Nexus 2025 | October 27-30, 2025
Other/Multi
Patient characteristics, treatment patterns, and real-world outcomes among patients in the US with human epidermal growth factor receptor 2-expressing solid tumors
Anuj Shah
Oral
Dato-DXd, T-DXd, Valemetostat
AACR 2025 | April 25-29, 2025
Other/Multi
Preclinical assessment of valemetostat, a dual inhibitor of EZH2 and EZH1, combined with trastuzumab deruxtecan and datopotamab deruxtecan for multiple solid tumors
Daisuke Honma
Poster
R-DXd
ASCO 2025 | May 30-June 3,2025
Other/Multi
REJOICE-PanTumor01: A phase 2 signal-seeking study of raludotatug deruxtecan (R-DXd) in patients with advanced or metastatic solid tumors
Laurence Albiges
Mini-Oral
T-DXd
AACR 2025 | April 25-29, 2025
Other/Multi
Serum proteomics analysis: Potential biomarkers and mechanisms of trastuzumab deruxtecan (T-DXd)–related interstitial lung disease/pneumonitis (ILD)
Kevin Contrepois
Poster
T-DXd
AACR 2025 | April 25-29, 2025
Other/Multi
The role of NHEJ/HR mediated DSB repair in cancer cell sensitivity to payload of T-DXd
Len W. Katsumata
